About Latigo Bio
Positioned to change the treatment paradigm of pain medicines
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Thousand Oaks, CA
- Company type
- Public Company
- Company profile name
- Latigo Biotherapeutics, Inc.
Latigo Biotherapeutics (Nasdaq: LTGO) is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction, with the goal to provide effective, rapid-acting pain relief. Latigo’s lead product candidate, LTG-001, is an oral Nav1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain.
Company locations
Thousand Oaks, CA, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
Business areas
- Biotechnology
- Health Care
- Medical
- Therapeutics
On LinkedIn
- Followers
- 9,850
- People linked to this company
- 63
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
300,000,000 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.